Global Information
회사소개 | 문의 | 위시리스트

활막육종(SS) : 시장 인사이트, 역학, 시장 예측(2028년)

Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast - 2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 11월 상품 코드 773910
페이지 정보 영문 151 Pages
가격
US $ 6,250 ₩ 7,367,000 PDF by E-mail (Single User License)
US $ 12,500 ₩ 14,735,000 PDF by E-mail (Site License)
US $ 18,750 ₩ 22,102,000 PDF by E-mail (Global License)


활막육종(SS) : 시장 인사이트, 역학, 시장 예측(2028년) Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast - 2028
발행일 : 2019년 11월 페이지 정보 : 영문 151 Pages

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)에서 활막육종(SS : Synovial Sarcoma)의 2017년 이환 수는 2,091명, 시장 규모는 약 5,943만 달러로 추산되고 있습니다.

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 활막육종(SS) 시장을 조사했으며, 질병 개요 및 현행 치료법, 출시 치료제 및 신약의 개요, 전체 및 각국의 시장 동향, 역학적 예측, 시장 규모, 부위·연령·성별·병기별 이환 수의 추이와 예측, 미충족 요구, 시장 성장요인 및 장벽 등을 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 활막육종(SS) 시장의 개요

  • 시장 점유율(실적)
  • 시장 점유율(예측)

제3장 질병 배경과 개요

  • 서론
  • 아형
  • 원인과 위험인자
  • 증상
  • 병태생리
  • 유전적 측면
  • 악성도 분류와 병기 분류
  • 진단
  • 예후
  • 활막육종의 전이성 바이오마커

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 주요 7개국의 총이환 수
  • 주요 7개국의 진단 이환 수

제5장 활막육종(SS)의 역학 : 국가별

  • 미국
    • 가정과 근거
    • 총이환 수
    • 진단 수
    • 진단 이환 수 : 부위별
    • 진단 이환 수 : 성별
    • 진단 이환 수 : 연령별
    • 진단 이환 수 : 병기별
  • EU 5개국
    • 독일
      • 가정과 근거
      • 총이환 수
      • 진단 수
      • 진단 이환 수 : 부위별
      • 진단 이환 수 : 성별
      • 진단 이환 수 : 연령별
      • 진단 이환 수 : 병기별
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본
    • 가정과 근거
    • 총이환 수
    • 진단 수
    • 진단 이환 수 : 부위별
    • 진단 이환 수 : 성별
    • 진단 이환 수 : 연령별
    • 진단 이환 수 : 병기별

제6장 치료 및 관리 가이드라인

  • 유럽 의학 종양 학회 - 희귀 성인 고형암의 임상 진료 가이드라인(ESMO-EURACAN-CGP)
  • 연부조직육종 관리에 관한 영국의 가이드라인
  • 연부조직육종 진단과 치료의 개선을 목적으로 한 NICE 가이드라인

제7장 미충족 요구

제8장 출시 치료제

  • Yondelis(Trabectadin) : PharmaMar
    • 제품 개요
    • 규제 마일스톤
    • 제조
    • 라이선스
    • 특허
    • 안전성과 유효성
    • 제품 개요
  • Pazopanib : Novartis
    • 작용기서
    • 제품 개발 동향

제9장 신약

  • Tazemetostat : Yondelis
    • 제품 개요
    • 제품 개발 동향
    • 임상 개발
    • 임상시험 정보
    • 제품 개요
  • ADP-A2M4 : Adaptimmune
  • Anlotinib(AL3818) : Advenchen Laboratories

제10장 주요 7개국의 활막육종(SS) 시장 분석

  • 주요 조사 결과
  • 주요 7개국의 시장 규모

제11장 미국의 활막육종(SS) 시장 전망

  • 시장 규모
    • 전체 시장 규모
    • 시장 규모 : 선택 치료제별
    • 시장 규모 : 치료제별

제12장 EU 5개국의 활막육종(SS) 시장 전망

  • 독일
    • 전체 시장 규모
    • 시장 규모 : 선택 치료제별
    • 시장 규모 : 치료제별
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국

제13장 일본의 활막육종(SS) 시장 전망

  • 시장 규모
    • 전체 시장 규모
    • 시장 규모 : 선택 치료제별
    • 시장 규모 : 치료제별

제14장 시장 성장요인

제15장 시장 장벽

제16장 부록

  • 조사 방법

제17장 DelveInsight의 서비스 내용

제18장 면책사항

제19장 DelveInsight 소개

KSA 19.11.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Total Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 2: Total Diagnosed Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 3: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Table 4: Diagnosed Incidence of SS in the United States (2017-2028)
  • Table 5: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Table 6: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 7: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 8: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Table 9: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Table 10: Diagnosed Incidence of SS in Germany (2017-2028)
  • Table 11: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 12: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 13: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 14: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Table 15: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Table 16: Diagnosed Incidence of SS in France (2017-2028)
  • Table 17: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 18: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 19: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 20: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Table 21: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Table 22: Diagnosed Incidence of SS in Italy (2017-2028)
  • Table 23: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 24: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 25: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 26: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Table 27: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Table 28: Diagnosed Incidence of SS in Spain (2017-2028)
  • Table 29: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 30: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 31: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 32: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Table 33: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Table 34: Diagnosed Incidence of SS in the UK (2017-2028)
  • Table 35: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 36: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 37: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 38: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Table 39: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Table 40: Diagnosed Incidence of SS in Japan (2017-2028)
  • Table 41: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 42: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 43: Age Specific incident cases of SS in Japan (2017-2028)
  • Table 44: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
  • Table 45: Market Size of Synovial Sarcoma in 7MM in USD Million (2017-2028)
  • Table 46: Total Market Size of Synovial Sarcoma in the United States, USD Million (2017-2028)
  • Table 47: Total Market Size of Synovial Sarcoma by line of therapies in the United States, in USD Million (2017-2028)
  • Table 48: Total Market Size of Synovial Sarcoma by therapies in the United States, USD Million (2017-2028)
  • Table 49: Total Market Size of Synovial Sarcoma in Germany, USD Million (2017-2028)
  • Table 50: Total Market Size of Synovial Sarcoma by line of therapies in Germany, in USD Million (2017-2028)
  • Table 51: Total Market Size of Synovial Sarcoma by therapies in Germany, USD Million (2017-2028)
  • Table 52: Total Market Size of Synovial Sarcoma in France, USD Million (2017-2028)
  • Table 53: Total Market Size of Synovial Sarcoma by line of therapies in France, in USD Million (2017-2028)
  • Table 54: Total Market Size of Synovial Sarcoma by therapies in France, USD Million (2017-2028)
  • Table 55: Total Market Size of Synovial Sarcoma in Italy, USD Million (2017-2028)
  • Table 56: Total Market Size of Synovial Sarcoma by line of therapies in Italy, in USD Million (2017-2028)
  • Table 57: Total Market Size of Synovial Sarcoma by therapies in Italy, USD Million (2017-2028)
  • Table 58: Total Market Size of Synovial Sarcoma in Spain, USD Million (2017-2028)
  • Table 59: Total Market Size of Synovial Sarcoma by line of therapies in Spain, in USD Million (2017-2028)
  • Table 60: Total Market Size of Synovial Sarcoma by therapies in Spain, USD Million (2017-2028)
  • Table 61: Total Market Size of Synovial Sarcoma in The United Kingdom, USD Million (2017-2028)
  • Table 62: Total Market Size of Synovial Sarcoma by line of therapies in The United Kingdom, in USD Million (2017-2028)
  • Table 63: Total Market Size of Synovial Sarcoma by therapies in The United Kingdom, USD Million (2017-2028)
  • Table 64: Total Market Size of Synovial Sarcoma in Japan, USD Million (2017-2028)
  • Table 65: Total Market Size of Synovial Sarcoma by line of therapies in Japan, in USD Million (2017-2028)
  • Table 66: Total Market Size of Synovial Sarcoma by therapies in Japan, USD Million (2017-2028)

List of Figures

  • Figure 1: Subtypes of Synovial Sarcoma
  • Figure 2: Risk factors associated with Synovial Sarcoma
  • Figure 3: SYT-SSX fusion
  • Figure 4: Protein interaction domains involved in synovial sarcoma
  • Figure 5: Relationship between SS18, SS18-SSX and the BAF complex
  • Figure 6: Genomic changes associated with Synovial Sarcoma
  • Figure 7: Biomarkers in Synovial Sarcoma
  • Figure 8: Total Incident Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 9: Total Diagnosed Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 10: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Figure 11: Diagnosed Incidence of SS in the United States (2017-2028)
  • Figure 12: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Figure 13: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 14: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 15: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Figure 16: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Figure 17: Diagnosed Incidence of SS in Germany (2017-2028)
  • Figure 18: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 19: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 20: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 21: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Figure 22: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Figure 23: Diagnosed Incidence of SS in France (2017-2028)
  • Figure 24: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 25: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 26: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 27: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Figure 28: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Figure 29: Diagnosed Incidence of SS in Italy (2017-2028)
  • Figure 30: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 31: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 32: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 33: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Figure 34: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Figure 35: Diagnosed Incidence of SS in Spain (2017-2028)
  • Figure 36: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 37: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 38: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 39: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Figure 40: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Figure 41: Diagnosed Incidence of SS in the UK (2017-2028)
  • Figure 42: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 43: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 44: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 45: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Figure 46: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Figure 47: Diagnosed Incidence of SS in Japan (2017-2028)
  • Figure 48: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 49: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 50: Age Specific incident cases of SS in Japan (2017-2028)
  • Figure 51: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
  • Figure 52: The Multi-disciplinary judgment approach
  • Figure 53: Management of Localized clinically resectable STSs
  • Figure 54: Synovial Sarcoma unmet needs
  • Figure 55: Market Size of Synovial Sarcoma in 7MM in USD Million (2017-2028)
  • Figure 56: Total Market Size of Synovial Sarcoma in the United States, USD Millions (2017-2028)
  • Figure 57: Total Market Size of Synovial Sarcoma by line of therapies the United States, in USD Million (2017-2028)
  • Figure 58:Total Market Size of Synovial Sarcoma by therapies in the United States, USD Millions (2017-2028)
  • Figure 59: Total Market Size of Synovial Sarcoma in Germany, USD Millions (2017-2028)
  • Figure 60: Total Market Size of Synovial Sarcoma by line of therapies Germany, in USD Million (2017-2028)
  • Figure 61:Total Market Size of Synovial Sarcoma by therapies in Germany, USD Millions (2017-2028)
  • Figure 62: Total Market Size of Synovial Sarcoma in France, USD Millions (2017-2028)
  • Figure 63: Total Market Size of Synovial Sarcoma by line of therapies France, in USD Million (2017-2028)
  • Figure 64:Total Market Size of Synovial Sarcoma by therapies in France, USD Millions (2017-2028)
  • Figure 65: Total Market Size of Synovial Sarcoma in Italy, USD Millions (2017-2028)
  • Figure 66: Total Market Size of Synovial Sarcoma by line of therapies Italy, in USD Million (2017-2028)
  • Figure 67:Total Market Size of Synovial Sarcoma by therapies in Italy, USD Millions (2017-2028)
  • Figure 68: Total Market Size of Synovial Sarcoma in Spain, USD Millions (2017-2028)
  • Figure 69: Total Market Size of Synovial Sarcoma by line of therapies Spain, in USD Million (2017-2028)
  • Figure 70:Total Market Size of Synovial Sarcoma by therapies in Spain, USD Millions (2017-2028)
  • Figure 71: Total Market Size of Synovial Sarcoma in The United Kingdom, USD Millions (2017-2028)
  • Figure 72: Total Market Size of Synovial Sarcoma by line of therapies The United Kingdom, in USD Million (2017-2028)
  • Figure 73:Total Market Size of Synovial Sarcoma by therapies in The United Kingdom, USD Millions (2017-2028)
  • Figure 74: Total Market Size of Synovial Sarcoma in Japan, USD Millions (2017-2028)
  • Figure 75: Total Market Size of Synovial Sarcoma by line of therapies Japan, in USD Million (2017-2028)
  • Figure 76:Total Market Size of Synovial Sarcoma by therapies in Japan, USD Millions (2017-2028)
  • Figure 77: Synovial Sarcoma market drivers
  • Figure 78: Synovial Sarcoma market barriers

DelveInsight's 'Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Synovial Sarcoma from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Synovial Sarcoma (SS) - Disease Understanding and Treatment Algorithm

Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8-10% of all soft tissue sarcomas (STS). Synovial Sarcoma is generally divided into three histological subtypes: monophasic, biphasic, and poorly differentiated and can affect patients of any age, although it is most common in adolescents and adults younger than 30 years of age. In the adolescent patient population, SS is considered the most common sarcoma subtype. The exact underlying cause of synovial sarcoma is poorly understood. However, studies show that a certain genetic change is identified in more than maximum number of cases.

The DelveInsight Synovial Sarcoma (SS) market report gives the thorough understanding of the Synovial Sarcoma by including details such as disease definition, classification, symptoms, genetics factors, risk factors, grading and staging, biomarkers, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Synovial Sarcoma in the US, Europe and Japan.

Synovial Sarcoma Epidemiology

The Synovial Sarcoma (SS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases , diagnosed incident cases, Site-specific incidence, gender-specific incidence, age-specific incidence, stage-specific incidence) scenario of synovial sarcoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of Incident cases of Synovial Sarcoma (SS) in 7 MM was found to be 2091 in the year 2017.

Synovial Sarcoma Drug Chapters

This segment of the Synovial Sarcoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Surgery remains the cornerstone of treatment and the only curative locoregional approach of localized resectable Soft Tissue Sarcoma including Synovial Sarcoma cases. While considering the overall disease management perspective, first-line treatment usually consists of wide margin surgery plus radiotherapy. Chemotherapy forms the first line of defense to treat most metastatic sarcomas with SS being no exception. As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by a watchful waiting approach to assess the optimum response.

Synovial Sarcoma Market Outlook

The Synovial Sarcoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Synovial Sarcoma in 7MM was found to be USD 59.43 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Synovial Sarcoma, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Synovial Sarcoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Synovial Sarcoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Synovial Sarcoma Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Synovial Sarcoma Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Synovial Sarcoma market
  • Organize sales and marketing efforts by identifying the best opportunities for A Synovial Sarcoma market
  • To understand the future market competition in the Synovial Sarcoma market.

Table of Contents

1. Key Insights

2. Synovial Sarcoma Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Synovial Sarcoma Market in 2017
  • 2.2. Market Share (%) Distribution of Synovial Sarcoma Market in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Subtypes
  • 3.3. Causes and risk factors
  • 3.4. Symptoms
  • 3.5. Pathophysiology
  • 3.6. Genetic aspect of synovial sarcoma
  • 3.7. Grading and staging of soft tissue sarcoma
  • 3.8. Diagnosis
  • 3.9. Prognosis
  • 3.10. Metastatic biomarkers in Synovial Sarcoma

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Incident Patient Population of Synovial Sarcoma
  • 4.3. 7MM Diagnosed Incident Patient Population of Synovial Sarcoma

5. Country Wise-Epidemiology of Synovial Sarcoma

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Incident Cases of SS
    • 5.1.3. Diagnosed Incidence of SS
    • 5.1.4. Site Specific Diagnose incident cases of SS
    • 5.1.5. Gender Specific diagnosed incident cases of SS
    • 5.1.6. Age Specific diagnosed incident cases of SS
    • 5.1.7. Stage Specific diagnosed Incident of cases of SS
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Total Incident Cases of SS
    • 5.3.2. Diagnosed Incidence of SS
    • 5.3.3. Site Specific diagnosed incident cases of SS
    • 5.3.4. Gender Specific diagnosed incident cases of SS
    • 5.3.5. Age Specific diagnosed incident cases of SS
    • 5.3.6. Stage Specific diagnosed Incident of cases of SS
  • 5.4. France
    • 5.4.1. Total Incident Cases of SS
    • 5.4.2. Diagnosed Incidence of SS
    • 5.4.3. Site Specific diagnosed incident cases of SS
    • 5.4.4. Gender Specific diagnosed incident cases of SS
    • 5.4.5. Age Specific diagnosed incident cases of SS
    • 5.4.6. Stage Specific diagnosed Incident of cases of SS
  • 5.5. Italy
    • 5.5.1. Total Incident Cases of SS
    • 5.5.2. Diagnosed Incidence of SS
    • 5.5.3. Site Specific diagnosed incident cases of SS
    • 5.5.4. Gender Specific diagnosed incident cases of SS
    • 5.5.5. Age Specific diagnosed incident cases of SS
    • 5.5.6. Stage Specific diagnosed Incident of cases of SS
  • 5.6. Spain
    • 5.6.1. Total Incident Cases of SS
    • 5.6.2. Diagnosed Incidence of SS
    • 5.6.3. Site Specific diagnosed incident cases of SS
    • 5.6.4. Gender Specific diagnosed incident cases of SS
    • 5.6.5. Age Specific diagnosed incident cases of SS
    • 5.6.6. Stage Specific diagnosed Incident of cases of SS
  • 5.7. United Kingdom
    • 5.7.1. Total Incident Cases of SS
    • 5.7.2. Diagnosed Incidence of SS
    • 5.7.3. Site Specific diagnosed incident cases of SS
    • 5.7.4. Gender Specific incident cases of SS
    • 5.7.5. Age Specific diagnosed incident cases of SS
    • 5.7.6. Stage Specific diagnosed Incident of cases of SS
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Total Incident Cases of SS
    • 5.8.3. Diagnosed Incidence of SS
    • 5.8.4. Site Specific diagnosed incident cases of SS
    • 5.8.5. Gender Specific diagnosed incident cases of SS
    • 5.8.6. Age Specific diagnosed incident cases of SS
    • 5.8.7. Stage Specific diagnosed Incident of cases of SS

6. Guidelines for Treatment/ Management of Soft-Tissue Sarcoma

  • 6.1. European Society for Medical Oncology- European Reference Network for rare adult solid cancers Clinical Practice Guidelines (ESMO-EURACAN-CGP): for Soft-Tissue Sarcoma
  • 6.2. UK Guidelines for Management of Soft-tissue Sarcomas
  • 6.3. NICE Guidelines for Improving Diagnosis and Treatment of Soft-Tissue Sarcoma

7. Unmet needs

8. Marketed Drugs

  • 8.1. Yondelis (Trabectadin) - PharmaMar
    • 8.1.1. Product description
    • 8.1.2. Regulatory Milestones
    • 8.1.3. Manufacturing
    • 8.1.4. Licensing
    • 8.1.5. Patent
    • 8.1.6. Safety and Efficacy
    • 8.1.7. Product Profile
  • 8.2. Pazopanib: Novartis
    • 8.2.1. Product description
    • 8.2.2. Mechanism of action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Product Development Activities
    • 8.2.5. Safety and Efficacy
    • 8.2.6. Product Profile

9. Emerging drugs

  • 9.1. Tazemetostat: Yondelis
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Clinical development
    • 9.1.4. Clinical Trials Information
    • 9.1.5. Product Profile
  • 9.2. ADP-A2M4: Adaptimmune
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical development
    • 9.2.4. Clinical Trials Information
    • 9.2.5. Product Profile
  • 9.3. Anlotinib (AL3818): Advenchen Laboratories
    • 9.3.1. Product Description
    • 9.3.2. Product Development Activities
    • 9.3.3. Clinical development
    • 9.3.4. Clinical Trials Information
    • 9.3.5. Product Profile

10. Synovial Sarcoma: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Synovial Sarcoma in 7MM

11. The United States Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market Size of Synovial Sarcoma
    • 11.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 11.1.3. Total Market Size of Synovial Sarcoma by therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market Size of Synovial Sarcoma
    • 12.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.1.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Synovial Sarcoma
    • 12.2.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.2.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Synovial Sarcoma
    • 12.3.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.3.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Synovial Sarcoma
    • 12.4.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.4.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.5. The United Kingdom
    • 12.5.1. Total Market Size of Synovial Sarcoma
    • 12.5.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.5.3. Total Market Size of Synovial Sarcoma by therapies

13. Japan: Market Outlook

  • 13.1. Japan market Size
    • 13.1.1. Total Market Size of Synovial Sarcoma
    • 13.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 13.1.3. Total Market Size of Synovial Sarcoma by therapies

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Back to Top
전화 문의
F A Q